PDCD1 and non-small cell lung carcinoma: Recent phase III clinical trials revealed that patients with advanced NSCLC being treated with PD‐1/PD‐L1 inhibitors plus chemotherapy had more favourable survival benefits than those receiving only chemotherapy as the first line of treatment.5, 6, 7